FDA approves semaglutide for heart events
- On March 8, 2024, the FDA expanded Wegovy’s label, letting Novo Nordisk market semaglutide to cut heart attack, stroke, and cardiovascular death risk. - The approval rode on SELECT, a 17,604-patient trial where major cardiovascular events hit 6.5% on semaglutide versus 8.0% on placebo. - That turns a weight-loss drug into a heart-risk drug too — a much bigger, more reimbursable market.
Semaglutide just stopped being only a weight-loss story. The FDA cleared Wegovy in March 2024 to reduce the risk of cardiovascular death, heart attack, and stroke in adults who already have cardiovascular disease and also have obesity or overweight. That matters because heart doctors, insurers, and patients all understand those endpoints in a way they do not always understand “lost X% of body weight.” Basically, the drug moved from looking cosmetic-adjacent to looking life-saving. (fda.gov) ### What actually got approved? The FDA approved a new indication for Wegovy — the 2.4 mg semaglutide injection made by Novo Nordisk — for adults with established cardiovascular disease and either obesity or overweight. The label is specifically abo(fda.gov)lth” claim, and it is not for everyone who wants to lose weight. It is for a defined high-risk group. (fda.gov) ### Why is that a bigger deal than another weight-loss label? Because the hardest question around obesity drugs has been whether weight loss itself translates into fewer hard outcomes. People can argue about waistlines. They argue less about heart a(fda.gov)ives the drug a very different clinical identity — more like preventive cardiology, less like elective metabolic treatment. (fda.gov) ### What evidence convinced the FDA? The key trial was SELECT. It enrolled 17,604 adults age 45 or older with preexisting cardiovascular disease, a body-mass index of at least 27, and no history of diabetes. Patients got weekly semaglutide 2.4 mg or(fda.gov)p — a 20% relative risk reduction. That is the number that changed the conversation. (nejm.org) ### Why does “without diabetes” matter so much? Because semaglutide’s cardiovascular credibility was already strong in diabetes. The open question was whether the benefit would hold in people whose main metabolic issue was obesity or overweight rather than diabetes itself. SELECT answered yes. That matters scientifically — it suggests the ben(nejm.org)t opens a much broader pool of patients. (nejm.org) ### Does this mean the drug prevents heart disease? Not exactly. Wegovy is not approved to stop healthy people from ever developing heart disease. The approved use is narrower — adults who already have cardiovascular disease and also have obesity or overweight. Think of it less like a universal shield and more like an added layer of protection for people who are already in the danger zone. (fda.gov) ### What’s the catch? The benefit is real, but the drug is not frictionless. In SELECT, adverse events leading to permanent discontinuation were higher with semaglutide — 16.6% versus 8.2% with placebo. And the FDA label still carries the boxed warn(fda.gov)add-on. (nejm.org) ### Why does this change the market? Coverage tends to follow outcomes. A drug framed as weight loss can run into stigma, exclusions, and budget fights. A drug framed as reducing heart attack and stroke risk has a stronger case with payers and health systems. That does not guarantee easy access — cost and supply still matter — but it gives doctors a much sharper argument for prescribing it. (fda.gov) ### Bottom line The FDA did not just bless semaglutide as a slimmer’s drug with bonus perks. It recognized Wegovy as a cardiovascular risk-reduction drug for a specific high-risk population. That is the real shift — and it is why this approval landed far beyond the obesity market. (fda.gov)
